Raymond James Initiates Coverage On Ionis Pharmaceuticals with Strong Buy Rating, Announces Price Target of $63
Portfolio Pulse from Benzinga Newsdesk
Raymond James has initiated coverage on Ionis Pharmaceuticals with a Strong Buy rating and a price target of $63.
September 29, 2023 | 9:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals has been given a Strong Buy rating by Raymond James, with a price target of $63.
The Strong Buy rating from Raymond James is a positive signal for Ionis Pharmaceuticals. This could lead to increased investor interest and potentially a rise in the stock price in the short term. The price target of $63 also indicates a significant upside potential from the current levels.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100